It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Analysis of agonist-driven phosphorylation of G protein-coupled receptors (GPCRs) can provide valuable insights into the receptor activation state and ligand pharmacology. However, to date, assessment of GPCR phosphorylation using high-throughput applications has been challenging. We have developed and validated a bead-based immunoassay for the quantitative assessment of agonist-induced GPCR phosphorylation that can be performed entirely in multiwell cell culture plates. The assay involves immunoprecipitation of affinity-tagged receptors using magnetic beads followed by protein detection using phosphorylation state-specific and phosphorylation state-independent anti-GPCR antibodies. As proof of concept, five prototypical GPCRs (MOP, C5a1, D1, SST2, CB2) were treated with different agonizts and antagonists, and concentration-response curves were generated. We then extended our approach to establish selective cellular GPCR kinase (GRK) inhibitor assays, which led to the rapid identification of a selective GRK5/6 inhibitor (LDC8988) and a highly potent pan-GRK inhibitor (LDC9728). In conclusion, this versatile GPCR phosphorylation assay can be used extensively for ligand profiling and inhibitor screening.
A G protein-coupled receptors (GPCRs) phosphorylation assay for cell culture plates can be used for ligand profiling and inhibitor screening, as evidenced by the identification of two GRK inhibitor compounds.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Universitätsklinikum Jena, Institut für Pharmakologie und Toxikologie, Friedrich-Schiller-Universität Jena, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224); 7TM Antibodies GmbH, Jena, Germany (GRID:grid.275559.9)
2 7TM Antibodies GmbH, Jena, Germany (GRID:grid.275559.9)
3 Universitätsklinikum Jena, Institut für Pharmakologie und Toxikologie, Friedrich-Schiller-Universität Jena, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224)
4 Universitätsklinikum Jena, Institut für Molekulare Zellbiologie, CMB—Center for Molecular Biomedicine, Friedrich-Schiller-Universität Jena, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224)
5 Lead Discovery Center GmbH, Dortmund, Germany (GRID:grid.505582.f)
6 University of Innsbruck, Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), Innsbruck, Austria (GRID:grid.5771.4) (ISNI:0000 0001 2151 8122)
7 University of Wuerzburg, Rudolf Virchow Center, Center for Integrative and Translational Bioimaging, Wuerzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)